DelMar Pharmaceuticals, Inc. (DMPI) financial statements (2020 and earlier)

Company profile

Business Address 12707 HIGH BLUFF DR., SUITE 200
SAN DIEGO, CA 92130
State of Incorp. NV
Fiscal Year End June 30
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
TTM
6/30/2019
6/30/2018
6/30/2017
6/30/2016
6/30/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments646762
Cash and cash equivalents646762
Receivables     0
Prepaid expense001100
Deferred costs     1
Other undisclosed current assets00000 
Total current assets:747863
Noncurrent Assets
Intangible assets, net (including goodwill)00000 
Intangible assets, net (excluding goodwill)00000 
Total noncurrent assets:00000 
Other undisclosed assets     0
TOTAL ASSETS:747863
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:121111
Other undisclosed accounts payable and accrued liabilities121111
Derivative instruments and hedges, liabilities   0  
Due to related parties000000
Total current liabilities:122111
Noncurrent Liabilities
Liabilities, other than long-term debt  0012
Derivative instruments and hedges, liabilities  0012
Other undisclosed noncurrent liabilities    00
Total noncurrent liabilities:  0013
Total liabilities:122113
Stockholders' equity
Stockholders' equity attributable to parent, including:52575(1)
Preferred stock     0
Common stock000000
Additional paid in capital56514337292
Accumulated other comprehensive income000000
Accumulated deficit(64)(61)(52)(41)(32)(19)
Warrants and rights outstanding878520
Other undisclosed stockholders' equity attributable to parent5566716
Total stockholders' equity:52575(1)
TOTAL LIABILITIES AND EQUITY:747863

Income statement (P&L) ($ in millions)

12/31/2019
TTM
6/30/2019
6/30/2018
6/30/2017
6/30/2016
6/30/2015
Operating expenses9811(8)(6)5
Operating income (loss):9811(8)(6)5
Nonoperating expense(0)(0)(0)(0)(3)(0)
Investment income, nonoperating0(0)(0)(0)(2)(1)
Foreign currency transaction gain (loss), before tax(0)00 (0)0
Interest and debt expense     0
Income (loss) before gain (loss) on sale of properties:9811(9)(9)4
Other undisclosed net loss(16)(16)(22)   
Net income (loss):(8)(8)(11)(9)(9)4
Other undisclosed net income (loss) attributable to parent16162217 (9)
Net income (loss) attributable to parent:98118(9)(4)
Preferred stock dividends and other adjustments0001  
Net income (loss) available to common stockholders, diluted:98119(9)(4)

Comprehensive Income ($ in millions)

12/31/2019
TTM
6/30/2019
6/30/2018
6/30/2017
6/30/2016
6/30/2015
Net income (loss):(8)(8)(11)(9)(9)4
Comprehensive income (loss):(8)(8)(11)(9)(9)4
Other undisclosed comprehensive loss, net of tax, attributable to parent     (0)
Comprehensive income (loss), net of tax, attributable to parent:(8)(8)(11)(9)(9)4

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: